Markets:

Overview

News

Currencies

International

Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

27.90 +0.03 (+0.11%)

Streaming Delayed Price Updated: 3:08 PM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? ↗

February 23, 2026

Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure.

Via Stocktwits

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗

February 23, 2026

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’.

Via Stocktwits

CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On ↗

February 20, 2026

Shares jumped over 14% on Thursday to their highest level and strongest session since December, when the company reported strong DMD trial results.

Via Stocktwits

‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% ↗

November 24, 2025

Via Stocktwits

Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗

November 10, 2025

Via Stocktwits

Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗

November 10, 2025

Via Stocktwits

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗

January 20, 2026

The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday.

Via Stocktwits

Here's Why This Biotechnology Skyrocketed by 439% in December ↗

January 09, 2026

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.

Via The Motley Fool

On Friday, there are stocks with unusual volume. Let's take a look. ↗

December 05, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 04, 2025

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Preview: Capricor Therapeutics's Earnings ↗

November 07, 2025

Via Benzinga

Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗

September 25, 2025

Via Stocktwits

Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗

December 04, 2025

DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder.

Via Stocktwits

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗

December 03, 2025

Capricor’s positive HOPE-3 results prompted Shkreli to call his short thesis a “bad call” after the therapy showed statistically significant skeletal and cardiac benefits.

Via Stocktwits

Why Did Capricor Therapeutics Stock Skyrocket Today? ↗

December 03, 2025

The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function.

Via Stocktwits

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗

December 03, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗

December 03, 2025

After a volatile start to the week, markets are showing signs of stabilization.

Via Stocktwits

Topics Artificial Intelligence ETFs Economy

Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗

December 01, 2025

Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks.

Via Stocktwits

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗

November 10, 2025

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

Via Benzinga

Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗

November 04, 2025

Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency.

Via Stocktwits

Why Capricor Therapeutics Stock Is Surging Today ↗

September 25, 2025

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics.

Via Benzinga

Gapping stocks in Thursday's session ↗

September 25, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

Via Chartmill

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week ↗

September 03, 2025

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.

Via Benzinga

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting ↗

August 22, 2025

Biohaven shares rise as FDA removes advisory committee meeting for troriluzole in spinocerebellar ataxia, with decision expected in late 2025.

Via Benzinga

C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗

August 11, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.